An official website of the United States government
An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer
Trial Status: complete
The primary purpose of this study is to determine whether Nivolumab will improve
disease-free survival compared with placebo.
Inclusion Criteria
Diagnosed with Stage II/III carcinoma of the esophagus or gastroesophageal junction
Completed pre-operative chemo radiotherapy followed by surgery
Diagnosed with residual pathologic disease after being surgically rendered free of disease with negative margins following complete resection
Exclusion Criteria
Diagnosed with cervical esophageal carcinoma
Diagnosed with Stage IV resectable disease
Did not receive concurrent chemoradiotherapy prior to surgery
Participants who have received a live/attenuated vaccine within 30 days of the first treatment Other protocol defined Inclusion/exclusion criteria could apply
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02743494.
Locations matching your search criteria
United States
District of Columbia
Washington
MedStar Georgetown University Hospital
Status: Active
Name Not Available
Illinois
Chicago
University of Chicago Comprehensive Cancer Center
Status: Active
Contact: Daniel Virgil Thomas Catenacci
Phone: 773-834-0475
Maryland
Baltimore
Johns Hopkins University/Sidney Kimmel Cancer Center
